Upcoming LymPro Milestones • LP-002 Full Data
Post# of 30028
Posted On: 12/06/2014 7:52:37 PM
Upcoming LymPro Milestones
• LP-002 Full Data Set from 140 patients (70 AD –mild to severe, 70 HC)
• Assay Validation at Icon
• IUO Launch
• CLIA Approval
• CE Mark
• Product launch at Icon Central Laboratories in process
• Preparing for spin-off / monetization
Upcoming Eltoprazine Milestones
• IND Submission/approval
• Phase 2b Initiation in PD LID in process
• Full enrollment
• Full data set
• End of Phase 2 meeting in Adult ADHD
Upcoming MANF Milestones
• ODD in RP w/FDA
• ODD applications w/FDA in 2nd retinal indication and RP w/EMA
• Drug Delivery Data in Parkinson’s disease
• Initiation GMP Manufacturing
ESS-W - Life-saving treatment for severe burns
• Orphan drug designation granted
• Phase 1 / 2 initiation in Q2/2015
http://ir.amarantus.com/presentations
• LP-002 Full Data Set from 140 patients (70 AD –mild to severe, 70 HC)
• Assay Validation at Icon
• IUO Launch
• CLIA Approval
• CE Mark
• Product launch at Icon Central Laboratories in process
• Preparing for spin-off / monetization
Upcoming Eltoprazine Milestones
• IND Submission/approval
• Phase 2b Initiation in PD LID in process
• Full enrollment
• Full data set
• End of Phase 2 meeting in Adult ADHD
Upcoming MANF Milestones
• ODD in RP w/FDA
• ODD applications w/FDA in 2nd retinal indication and RP w/EMA
• Drug Delivery Data in Parkinson’s disease
• Initiation GMP Manufacturing
ESS-W - Life-saving treatment for severe burns
• Orphan drug designation granted
• Phase 1 / 2 initiation in Q2/2015
http://ir.amarantus.com/presentations
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼